The insulinoma-associated 1 (INSM1) gene is expressed exclusively during early embryonal development, but has been found reexpressed at high levels in neuroendocrine tumors. The regulatory region of the INSM1 gene is therefore a potential candidate for regulating expression of a therapeutic gene in transcriptionally targeted cancer gene therapy against neuroendocrine tumors. We analyzed expression of a reporter gene from a 1.7 kb region of the INSM1 promoter in a large number of small-cell lung cancer (SCLC) cell lines. This INSM1 promoter region showed very high levels of expression in most of the SCLC cell lines and expression was absent in cell lines of non-neuroendocrine origin. Inclusion of the general transcriptional enhancer from SV40 compromised the specificity of the promoter and did not enhance transcription in most of the SCLC cell lines. For comparison, the region of the gastrin releasing peptide (GRP) previously suggested for SCLC gene therapy was analyzed in a similar manner. High expression was observed for a number of cell lines, but unlike for the INSM1 promoter, reporter gene expression from the GRP promoter did not correlate to the relative GRP mRNA levels, demonstrating that this region may not contain all necessary regulatory elements. Expression of the suicide gene herpes simplex virus thymidine kinase (HSV-TK) from the INSM1 promoter in combination with treatment with the prodrug ganciclovir (GCV) caused a significant increase in GCV sensitivity specifically in INSM1-expressing cell lines. The INSM1 promoter is therefore a potential novel tool for transcriptionally targeted gene therapy for neuroendocrine tumors.
Introduction
Lung cancer is one of the most common causes of cancer death. Small-cell lung cancer (SCLC) accounts for approximately 20% of lung cancers and is characterized by neuroendocrine features, fast growth and early dissemination. The current treatment is chemotherapy and radiotherapy, 1 but despite a high rate of initial response, the disease almost invariably recurs in a chemoand radiation-resistant form. As the overall 5-year survival rate is less than 5%, new modalities for treatment are highly in demand. A large number of novel targeted treatments such as molecular targeted therapies and immunotherapies are in trial, but so far most of the preclinical and clinical results have been negative. 1, 2 Gene therapy is showing increasing promise as a supplement or alternative to current treatments in a variety of cancers. As SCLC is a disseminated disease, treatment must be administered systemically. This requires that the cytotoxic treatment is targeted to the cancer cells to reduce damage to normal tissues. Although the development of suitable delivery vehicles for gene transfer is far from accomplished, it is becoming increasingly evident that uptake of genes through surface molecules will not suffice as a cancer-specific targeting factor. Therefore, it is compulsory that expression of a therapeutic gene, such as a suicide gene, exclusively occurs in the cancer cells. This can be achieved by expression of the therapeutic gene from a tumor-specific promoter. 3 Several strategies utilizing transcriptional targeting have been suggested for SCLC. One scheme takes advantage of the overexpression of the myc family protooncogenes in SCLC, often a result of amplification of the myc genes. 4 By inserting multiple Myc-Max transcription factor response elements into a basal promoter, a high expression of a suicide gene resulted in significant increase in prodrug sensitivity in SCLC cell lines and xenografted tumors with high myc expression. 5, 6 Therefore this strategy appears to be sufficiently active for therapy, but it may represent a problem, that the myc family is expressed at low levels in normal tissues. An alternative is to use the promoter from the human telomerase reverse transcriptase gene (hTERT) -a gene normally only expressed in fetal and tumor cells. Recently it was shown that expression of a suicide gene from the hTERT promoter caused 50% reduction of cell growth of an SCLC cell line, but not of a normal fibroblast cell line in vitro. 7 Other strategies take advantage of the neuroendocrine nature of SCLC. The promoters for arginine vasopressin and the cell surface antigen CD24 genes have been suggested, but have not yet been tested with therapeutic genes. 8, 9 The neuron-specific enolase promoter has been tried for gene therapy for SCLC, but expression of a suicide gene from this promoter could not mediate cell death. 10 Both tumor expression and serum levels of the gastrin releasing peptide (GRP) has been used as a marker for SCLC. 11, 12 The GRP promoter is the only promoter, when regulating the expression of a suicide gene, which has of yet shown a significant cytotoxicity for SCLC both in vitro and in vivo. 13, 14 Although overexpressed in SCLC, GRP is also expressed in the adult in the neurons of the brain, gastrointestinal and reproductive tract, and in the neuroendocrine cells of the lung. Therefore, whereas the GRP promoter is potential for localized transcriptionally targeted cancer gene therapy for SCLC, the low expression in normal tissues may impose adverse effects for systemic treatment.
To identify other genes with high and specific expression in SCLC from which the promoter regions potentially could be used for gene therapy, we have performed a global gene expression analysis on a large panel of SCLC cell lines and xenografts. The expression levels were compared to a large panel of normal, representative tissues. 15 One of the genes identified was the insulinomaassociated 1 (INSM1, IA-1). The high expression of this gene has previously been observed in a number of SCLC tumors 16, 17 and other SCLC cell lines. 18, 19 INSM1 is exclusively expressed in tumors of neuroendocrine origin, such as pheochromocytoma, medullary thyroid carcinoma, insulinoma, pituitary tumor and SCLC, 18 and not in other types of tumors nor any adult tissues. INSM1 was originally identified using a subtraction library from human insulinomas 18 and was recognized as a nuclear transcriptional repressor. [20] [21] [22] Its expression is limited to regions undergoing neuroendocrine differentiation in the embryo and is believed to play a role in the complex cascade of factors important for neuroendocrine development. 22 A functional analysis of a 2.1 kb region of the INSM1 promoter region identified a number of positive and negative regulatory cis-elements.
23-25
For transcriptionally targeted gene therapy, it is imperative that the high expression levels of a gene is not caused by amplification, aberrant methylation, etc. of the promoter, as these features cannot be reproduced in a targeting vector. The high levels of INSM1 mRNA in SCLC and other neuroendocrine tumors seems a result of aberrant expression of transcription factors and a relatively short region of the INSM1 promoter contains the necessary regulatory regions for specific expression. These features make the INSM1 promoter particularly attractive for transcriptionally targeted gene therapy. We therefore examined expression from this promoter region in a large panel of SCLC cell lines and some non-SCLC cell lines in order to examine its potential for targeted gene therapy for SCLC. In the present study, we demonstrate very high and specific expression from the INSM1 promoter correlating to the relative expression levels of INSM1 mRNA. In addition, we show here for the first time, that expression of the suicide gene herpes simplex virus thymidine kinase (HSV-TK) from this promoter region in conjunction with ganciclovir (GCV) treatment effectively and specifically increased GCV sensitivity in INSM1-expressing cells. Expression from the GRP promoter was assessed in a similar manner for comparison.
Results
A number of cell lines were chosen to evaluate gene expression levels of the reporter gene luciferase from the cloned GRP and INSM1 promoter regions to determine the potency of their activities and to compare the relative expression levels with the endogenous mRNA levels of GRP and INSM1. The SCLC cell lines were selected on the basis of having different growth rates and morphologies and included both suspension and adherent cells. For comparison, several human tumor cell lines with no neuroendocrine features were selected -the epidermoid carcinoma cell line A431, the glioblastoma cell line U-87 MG, the breast adenocarcinoma MDA-MB-231, the nonsmall cell lung carcinoma NCI-H358, and the head and neck squamous cell carcinoma HN5. To evaluate expression in non-tumor cell lines, the human non-immortalized fibroblast cell lines CCD-32Lu and CCD-19Lu were included.
GRP promoter
The proximal 1.25 kb region of the GRP promoter has been suggested for targeted gene therapy for SCLC. 13 An oligonucleotide array analysis showed that GRP mRNA was expressed in 50% of SCLC cell lines at high levels 15 ( Figure 1a ) and the expression levels were confirmed by semiquantitative RT-PCR (data not shown). Both the array analysis and the RT-PCR confirmed low expression in several normal tissues, including the lung, stomach, testis, thyroid and trachea (data not shown).
Luciferase activity from the GRP promoter was measured after transient transfections. As the cell lines have very different transfection efficiencies, the luciferase activity was compared to the expression from the strong constitutively active, viral SV40 promoter with the SV40 enhancer, assuming that the transfection efficiencies for the two plasmids are the same. Low, but detectable expression was seen in the non-SCLC lines from the GRP promoter. High expression of luciferase was observed in many of the SCLC cell lines (up to 4 times the activity of the SV40 promoter) (Figure 1b ), but the relative activities did not correlate to the relative expression levels of GRP mRNA as measured by the array analysis (Figure 1a ). Several SCLC cell lines, which do not express GRP mRNA, displayed high expression of the reporter gene from the 1.25 kb GRP promoter region. Therefore, although this promoter region directs high transcriptional activity in SCLC cell lines, it is not sufficient for correct transcriptional regulation.
INSM1 promoter
The oligonucleotide array analysis performed by Pedersen et al. 15 showed high expression of INSM1 mRNA in the majority of the SCLC cell lines (Figure 2a ). Both the microarray analysis and a semiquantitative RT-PCR validation showed high expression of INSM1 mRNA in the majority of the SCLC cell lines tested (85%) and mRNA was absent in all normal tissues except a very weak signal in adrenal gland. 15 None of the non-SCLC cell lines expressed INSM1 mRNA as determined by RT-PCR (Figure 2b ). The activity of the proximal 1.7 kb region of the human INSM1 promoter was tested in a similar manner as for the GRP promoter with the reporter gene luciferase (Figure 2c ). The expression levels were up to 4 times higher than that observed for the GRP promoter and up to 15 times that of the SV40 promoter with the SV40 enhancer. In particular, the relative expression levels in the luciferase assay correlated well with the array analysis of INSM1 mRNA levels ( Figure 2a ). There was no detectable expression in the other tumor or fibroblast cell lines. This demonstrates that this region of the INSM1 promoter appears to have all the regulatory elements necessary for high and specific expression.
Effect of the SV40 enhancer
Although the reporter gene expression from the INSM1 promoter was very high, the SV40 enhancer was included in the luciferase plasmid with the INSM1 promoter in an attempt to further increase the activity. The SV40 enhancer has been reported to enhance the expression of a number of heterologous promoters. 26, 27 For comparison, the expression from the SV40 promoter was also tested with and without the SV40 enhancer.
The results from transient transfections are shown in Figure 3 . The effect of the enhancer was very different for the various cell lines, resulting in both upregulation, downregulation or had no effect. Cell lines, for which the SV40 enhancer gave increased expression for both the SV40 and INSM1 promoters are shown in Figure 3a .
Markedly, all the cell lines in this group have no or very low expression from the INSM1 and SV40 promoters without the enhancer and all have low or no expression of INSM1. In cell lines with medium to high activity from the INSM1 promoter, insertion of the enhancer either slightly reduced the activity of the promoters or had no effect ( Figure 3b ). Therefore, insertion of the SV40 enhancer did not increase the activity of the INSM1 promoter in the cell lines in which it was desired (high INSM1 expression), but on the contrary had no effect or actually decreased activity in these lines. The only cell lines where the SV40 enhancer had an activating effect was in the cell lines in which the INSM1 promoter is not normally active.
Suicide therapy -transient expression of HSV-TK
Expression of a suicide gene by stable transfection or transduction followed by administration of a prodrug has been applied as gene therapy for many different types of cancer cells and tumors. One of the most widely used suicide genes is the HSV-TK gene, which, unlike its mammalian counterpart, can convert the nontoxic prodrug GCV into phosphorylated GCV, which is highly toxic (for reviews see Yazawa et al. 28 and Fillat et al. 29 ). To examine if the INSM1 promoter possessed sufficient activity for suicide gene therapy, the INSM1 promoter was cloned to regulate expression of HSV-TK. For comparison, this gene was also cloned to be expressed by the GRP promoter and the SV40 promoter with the SV40 enhancer. For these experiments, only cell lines with high and comparable transfection efficiencies were used (approximately 80% as judged visually by transfection with an EGFP coding plasmid -data not shown). After transient transfections of two cell lines with low or no INSM1 and GRP expression (Figure 4a and b), significantly increased sensitivity to GCV was only observed for the cells transfected with HSV-TK expressed from the SV40 promoter with the enhancer (IC 50 1-4 mM). Above 100 mM the prodrug displays general toxicity. In contrast, two SCLC cell lines with high expression from the INSM1 and GRP promoters showed a significant increase in sensitivity to GCV for HSV-TK expressed from the SV40, INSM1 and GRP promoters (Figures 4c  and d) . Although the expression levels of luciferase from the INSM1 promoter was up to 10-fold the levels of the SV40 promoter in these two cell lines, the GCV sensitivities were comparable. The luciferase expression levels from the GRP promoter was several fold above expression from the SV40 promoter, but HSV-TK expressed from the GRP promoter did not induce as high sensitivity to GCV, as when expressed from the SV40 promoter. The IC 50 values were 6 times higher for the GRP promoter (60 mM) than for the SV40 and INSM1 promoters (IC 50 10 mM) in the two cell lines after 5 days of GCV treatment.
Suicide therapy -stable expression of HSV-TK As the results presented above represent a balance between the transient expression of HSV-TK, the percentage of cells transfected and the time needed for efficient cell death, a SCLC cell line with high INSM1 expression (GLC 16), was stably transfected to express HSV-TK from the INSM1 promoter. The expression of HSV-TK mRNA was confirmed by RT-PCR (data not shown). The cell line was stable, as after 5 months of propagation without hygromycin selection, the HSV-TK mRNA level did not reduce, nor was there any reduction of the GCV sensitivity (data not shown). Using this cell line, it was possible to determine the time frame and efficiency of the treatment. At 2 days after addition of GCV, more than 50% of the cells were dead at 100 mM GCV, after 5 days more than 90% were dead ( Figure 5 ) and after 7 days 100% of the cells were dead at 100 mM GCV -a concentration of GCV which had no effect on the parental cell line, GLC 16. The observation that 100% of the cells died at this GCV concentration indicates that 100% of the cells express HSV-TK, as these cell lines display no bystander effect when grown as suspension cells in culture (see later). The IC 50 after 5 days was less than 0.3 mM GCV, thus demonstrating a significant increase in GCV sensitivity compared to the transiently transfected cells.
Discussion
Transcriptionally targeted suicide or other therapeutic gene therapy for cancer requires high activity and tumor specificity of the promoter. The GRP promoter has been suggested for gene therapy for SCLC 13, 14 and was therefore used for comparison of the potential of a A functional analysis of the GRP promoter has revealed several distal and proximal cis-regulatory regions. A negative regulatory element and a general enhancer region were found located between À5.6 and À2.6 kb and a tissue-specific region between À1.1 and À0.7 kb from the transcription start site. 30 The 1.25 kb proximal region of the GRP promoter gives high expression of a reporter gene in a GRP mRNA positive, but not in a GRP mRNAnegative SCLC cell line, nor in two other GRP mRNAnegative lines. 30 Stable expression or expression after adenoviral transduction of the suicide gene HSV-TK from this promoter region only resulted in highly increased sensitivity to the prodrug GCV in the GRP-positive cell line in vitro. In addition, significant tumor regression was observed with the stably transfected or adenoviral transduced cell line after GCV treatment in vivo. 13, 14 We tested the activity of this GRP promoter region for expression of the reporter gene luciferase in a large number of SCLC cell lines, five other tumor cell lines and two nonimmortalized fibroblast cell lines. By comparison to the relative GRP mRNA levels in the SCLC cell lines determined by the oligonucleotide array analysis, 15 we found high expression of luciferase from this promoter region in many SCLC cell lines for which endogenous GRP mRNA was not detectable and there was low, but detectable expression in several of the non-SCLC cell lines. Furthermore, the relative expression levels of luciferase in the GRP mRNA-positive cell lines did not correlate with the endogenous GRP mRNA levels. A distal negative regulatory element, which has been suggested to be responsible for suppression of GRP expression in non-SCLC, is not present in the cloned GRP promoter region 30 and may be necessary to include to obtain specificity. Therefore, the 1.25 kb region of the GRP promoter, although highly active in SCLC, may not be sufficient for regulation of expression of a therapeutic 
to GRP, and may therefore be aberrantly expressed in normal tissues after systemic delivery.
INSM1 mRNA is highly expressed in most SCLC cell lines, tumors and in the embryonal nervous system, but is not detectable in normal adult tissues. 15, 16, 19 A 1.7 kb region of the human INSM1 promoter coupled to a reporter gene has been demonstrated to confer correct tissue and developmental expression in transgenic mice. 25 We therefore examined expression of the luciferase gene regulated by this 1.7 kb proximal region of the INSM1 promoter in a similar manner as for the GRP promoter using the same panel of cell lines as for the GRP promoter. Transfection with the INSM1 promoter controlling luciferase expression resulted in many fold higher activity of luciferase in most of the SCLC cell lines compared to activity from the SV40 promoter with the SV40 enhancer and no activity in other cell lines, both of tumor and normal origin (Figure 2c) . Notably, the relative activities in the different cell lines correlated very closely with the relative INSM1 mRNA levels (Figure 2a) . This indicates that the high expression of INSM1 mRNA in the SCLC cell lines is not due to amplification of the gene in the cancer cells, nor deregulated methylation/ acetylation of the promoter region, but must be controlled by specific cellular factors reactivated in SCLC and that the 1.7 kb region of the promoter is sufficient for regulating high and specific expression in SCLC.
In analyses of the 2.1 kb region of the INSM1 promoter region, several regulatory regions were identified. 23 A negative regulatory region was identified at a position between À1.0 and À0.7 kb. The proximal À0.5 kb region was found to be sufficient for maximal and specific expression in a neuroendocrine cell line. 24 This region contains three transcription factor SP-1 binding sites, and SP-1 was demonstrated to bind these sites and enhance transcription. Three proximal and four distal E-boxes were identified. E-boxes are both positive and negative regulatory cis-elements, which bind the tissue-specific basic helix-loop-helix (bHLH) family of transcription factors as heterodimers with the ubiquitous proteins of the E-protein family. The bHLH family members are important for many tissue-specific developmental processes including neurogenesis, myogenesis and pancreatic development. The bHLH protein NeuroD1, known to be involved in neurogenic differentiation, was found to heterodimerize with the E-protein E47 and is essential for activation of transcription from the INSM1 promoter by binding to the most proximal E-box in the À0.5 kb region. 25 As INSM1 is a transcriptional repressor, which can downregulate expression of NeuroD1, 21 it appears that NeuroD1 and INSM1 may regulate the expression of one another. In the oligonucleotide array analysis performed by Pedersen et al. 15 many of the SCLC cell lines showed high expression of NeuroD1 mRNAalthough the levels did not correlate with the relative levels of INSM1 expression (unpublished data). Both the negative regulatory region and the tissue-specific proximal region containing the SP-1 sites and the NeuroD1-regulated E-box are present in the 1.7 kb promoter region. Our results therefore confirm that this region of the INSM1 promoter is sufficient for regulated and high gene expression.
Addition of the SV40 enhancer in gene therapy vectors has previously been shown to significantly enhance expression without loss of tissue specificity in the muscle 26 and liver. 27 Apart from being a general enhancer, the SV40 enhancer has the unique capacity to mediate nuclear import of plasmids, presumably by binding transcription factors, which are actively transported to the nucleus via the importin system of the nuclear pores. [31] [32] [33] As transfected plasmid DNA normally only reaches the nucleus after cell division, the ability to mediate active nuclear transport enables plasmids to be transcribed and translated in the absence of cell division. 34 This could be of importance when using nonviral gene therapy delivery systems, which do not possess intrinsic nuclear translocation abilities. Therefore, in an attempt to further increase the potency of the INSM1 promoter, the SV40 enhancer was inserted downstream of the luciferase gene in the reporter plasmid. Insertion of this enhancer resulted in expression of the reporter gene in five SCLC lines tested and in all the non-SCLC cell lines tested. These cell lines have no or very low activities from the SV40 and INSM promoters without the enhancer. Therefore, this enhancer caused the INSM1 promoter to loose its specificity. The enhanced transcription cannot be explained by the nuclear translocation effect of the enhancer, as all the cell lines with enhancer-induced expression have comparable or higher growth rates than the cell lines, where the enhancer had no or a negative effect.
Noticeably, all the cell lines where the SV40 enhancer had an activating effect on both the INSM1 and SV40 promoters have low or no INSM1 expression (without the enhancer). For cell lines with high INSM1 activity, there was no enhancement by inclusion of the SV40 enhancer for either of the INSM1 or SV40 promoters, and in some cases even loss of activity. The same tendency for all the cell lines tested was observed for the GRP promoter with and without the SV40 enhancer (data not shown). The activity of the SV40 enhancer is dependent on a number of transcription factors 35 and it is a possibility that an active INSM1 promoter may sequester some of these factors. Alternatively, as INSM1 is a transcription factor and the SV40 enhancer has a few potential INSM1 DNAbinding sites (unpublished data), the INSM1 protein may directly bind the enhancer and act as a repressor.
Other approaches to increase the activity in a cancerspecific manner could be attempted. For the CEA promoter, multimerization of E-boxes have been demonstrated to enhance both activity and specificity in a copy number related manner. 36 Therefore, multimerization of one or more of the E-boxes in the INSM1 promoter is a possibility. As there are no theoretical limitations to the amount of elements that can be included in a genetargeting vector, it may be possible to further increase the amount of the activating NeuroD1 by coexpressing this factor from the INSM1 promoter. Other alternatives could be the insertion of Myc-Max response elements, which in themselves confer high activity in SCLC and insulinomas, as these frequently have overexpression of the myc family. 4, 6, 37 It was essential to determine if the cloned INSM1 promoter region was sufficiently active to promote cell death when regulating the expression of a therapeutic gene. The GRP promoter and the SV40 promoter with the SV40 enhancer were both tested in a similar manner for comparison. The HSV-TK/GCV suicide gene system was chosen, as this is one of the most successful strategies developed so far. 28, 29 In addition to the advantage that GCV is a prodrug already approved for human use, the HSV-TK/GCV system displays 'bystander effects' -both locally and immune mediated. 38, 39 Traditionally in vitro assays with suicide genes are performed with virally transduced cell lines, where the suicide gene will be expressed in 100% of the cells with an active promoter. However, using cell lines with relative high transfection efficiencies (approx. 80%), we could demonstrate specific cellular toxicity after transient transfections with the HSV-TK constructs and treatment with GCV. Two cell lines with no or low expression from the GRP and INSM1 promoters and two SCLC cell lines with high expression of both GRP and INSM1 were chosen for this study. All the cell lines showed highly increased sensitivity to GCV, when HSV-TK was expressed from the SV40 promoter/enhancer. The two cell lines with no or low expression of GRP and INSM1 only displayed none or a slight increase in GCV sensitivity, when transfected with the HSV-TK gene regulated by the GRP or INSM1 promoters. In contrast, the two cell lines with high expression from the GRP and INSM1 promoters (NCI-H69 and GLC 16) showed markedly increased sensitivity to GCV with all the promoters.
Despite that the INSM1 and GRP promoters display several fold the activity of the SV40 promoter with the enhancer, when regulating luciferase expression in the NCI-H69 and GLC 16 cell lines, expression of HSV-TK from the GRP promoter was less efficient and the INSM1 promoter had the same efficiency as the SV40 promoter for inducing increased GCV sensitivity. The transfection with the HSV-TK controlled by the SV40 promoter without the enhancer showed the same GCV sensitivity as with the enhancer (data not shown). Therefore, this effect cannot be due to the nuclear targeting ability of the SV40 enhancer in cells undergoing cell cycle arrest due to accumulation of the toxic product of GCV.
Complete cell death was not achieved in these assays, as not all cells were transfected and the expression of HSV-TK was transient. However, as only 20-30% of the cells survive at 100 mM GCV after 5 days, this indicates that the majority of the transfected cells were killed by the treatment at this concentration and the surviving cells reflect the number of untransfected cells. To demonstrate this point, one of the cell lines with high activity from the INSM1 promoter (GLC 16) was stably transfected to express HSV-TK. This cell line displayed much higher GCV sensitivity than the transiently transfected cells and 100% cell death was obtained after 7 days exposure to 100 mM GCV. These experiments demonstrate that the INSM1 promoter is sufficiently active for suicide gene therapy.
One of the advantages of the HSV-TK/GCV suicide system is the presence of the 'bystander effect', which causes transfer of toxic nucleotides to neighboring cells via gap junctions. 38, 40 The stably expressing HSV-TK and the parental cell lines grow as a suspension cells in vitro and as expected, no 'bystander effect' could be 38 To increase the efficacy of suicide gene therapy for SCLC, it may therefore be beneficial to include an expression system for connexin 43 together with the suicide gene. In addition, several HSV-TK mutants have been generated, which not only increase the sensitivity for GCV many fold, but also increase the 'bystander effect'. 29, 39 Therefore, these may be better candidates as suicide genes than the wild-type HSV-TK. Alternatively, treatment with histone deacetylase inhibitors has been shown to increase the expression of connexin 43 and increase the 'bystander effect'. 41 In conclusion, we show here for the first time that a 1.7 kb region of the INSM1 promoter is sufficiently active for cancer suicide gene therapy and that this promoter region has all the regulatory elements necessary for cancer-specific expression in SCLC. As INSM1 mRNA has never been found in any adult tissues, the INSM1 promoter is particularly promising for regulating expression of a therapeutic gene for systemic delivery, even if the delivery system of a gene therapy vector is not absolutely cancer specific. Owing to the very high activity and tumor specificity, the INSM1 promoter appears superior to the other promoters suggested for targeted gene therapy for SCLC.
Materials and methods

Cell lines
The origin and propagation of the SCLC cell lines is described in detail in Pedersen et al. 15 The human nonimmortalized fibroblast cell lines CCD-32Lu, CCD19Lu, the human epidermoid carcinoma line A431, the human breast adenocarcinoma MDA-MB-231 were obtained from ATCC, the human glioblastoma cell line U-87 MG was obtained from Dr W Cavenee (San Diego, CA), the human non-small cell lung carcinoma NCI-H358 from Dr RJ Cristiano (Houston, TX) and the human head and neck squamous cell carcinoma HN5 from J Bartek (Copenhagen, Denmark). CCD-32Lu, HN5 and A4321 were propagated in DMEM, U-87MG and CCD19Lu in EMEM and H358 in RPMI, all supplemented with 10% fetal calf serum (FCS) and antibiotics. All cell culture reagents were from Invitrogen (Taastrup, Denmark).
Plasmid constructs SV40-LUC þ enhancer (pGL3-control) (Promega, Mannheim, Germany): This plasmid contains the SV40 promoter, the luciferase gene, the SV40 late polyadenylation signal and the SV40 enhancer. SV40-LUC: A plasmid without the enhancer (SV40-LUC) was constructed by inserting the KpnI-HindIII fragment containing the SV40 promoter into the KpnIHindIII sites of the promoterless and enhancerless pGL3-Basic (Promega, Mannheim, Germany).
GRP-LUC: The 1.25 kb region of the GRP promoter (À1145 to þ 110, GenBank S73265) was cloned by PCR using primers described in Inase et al. 13 and genomic DNA from the human cell line CCD32 Lu as template using Herculase s Enhanced DNA Polymerase (Stratagene, Belgium). The PCR product was inserted into the SmaI site of the promoterless vector pGL3-Basic (Promega, Mannheim, Germany).
GRP-LUC þ enhancer: The 1.25 kb GRP promoter was excised with KpnI and XhoI from GRP-LUC and inserted into the KpnI and XhoI sites of the pGL3-enhancer (Promega, Mannheim, Germany).
INSM1-LUC: Cloning of the 1.7 kb region (À1661 to þ 40) of the human INSM1 promoter region into pGL3-Basic has been described by Breslin et al. Control plasmid: pGL3-Basic (Promega, Mannheim, Germany) is a promoterless and enhancerless plasmid with the luciferase gene and SV40 late polyadenylation signal.
RT-PCR: RNA was isolated from cell lines using the RNeasy kit (Qiagen, Albertslund, Denmark). Reverse transcription was performed using Superscript RT III and PCR amplification using Platinum Taq Polymerase (Invitrogen, Taastrup, Denmark) with 25 cycles of amplification.
Primers 
Luciferase assays
In all, 0.2 Â 10 6 cells (adherent cells plated 1 day prior to transfection) were transfected in duplicate with 0.5 mg DNA using Lipofectamine 2000 in OPTIMEM (Invitrogen, Taastrup, Denmark) in 24-well dishes. After 3 h suspension cells were added to 10% FCS and adherent cells were changed to growth medium. At 48 h after transfection, cells were lysed in Passive Lysis Buffer (Promega, Mannheim, Germany) and luciferase activity was measured using the Luciferase Assay System (Promega, Mannheim, Germany). For each cell line in each experiment, luciferase activity was compared to the activity of SV40-LUC þ enhancer.
GCV assays of transiently transfected cells
In all, 2 Â 10 6 cells (adherent cells plated 1 day prior to transfection) were transfected with 3 mg plasmid using Lipofectamine 2000 in OPTIMEM (Invitrogen, Taastrup, Denmark) in six-well dishes. After 3 h suspension cells were added to 10% FCS and adherent cells were changed to growth medium. At 24 h after transfection, the cells were plated in duplicate at a density of 0.025 Â 10 6 cells in 100 ml medium containing GCV (Cymevene, Roche, Hvidovre, Denmark) in 96-well plates (NUNC). After 5 days (without change of medium or new addition of GCV), the proliferation was measured using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay (MTT) (Sigma, Broendby, Denmark) as described in Hansen et al. 42 For each cell line in each experiment, the data were normalized to no addition of GCV.
Stably expressing HSV-TK cell line
The SCLC cell line GLC 16 was stably transfected with by cotransfection of 5 Â 10 6 cells with 5 mg INSM1-HSV-TK and 0.5 mg pTK-Hyg (Clontech, BD Biosciences, Broendby, Denmark) using Lipofectamine 2000. After 24 h, the cells were transferred to a medium containing 1 mg/ml Hygromycin B (Invitrogen, Taastrup, Denmark) and a stably transfected cell line was generated (GLC 16-INSM1-HSV-TK).
GCV assays of stably transfected cells
The stably transfected GLC 16-HSV-TK and the parental GLC 16 cell lines were plated in duplicate at a density of 0.025 Â 10 6 cells in 100 ml medium containing GCV (Cymevene, Roche) in 96-well plates (NUNC, Slangerup, Denmark). After 2, 5 and 7days without change of media or addition of GCV, the proliferation was measured using the MTT assay as described above.
